Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 18/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.76 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.76 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.76 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.76 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20340577 | 0.91 | KRAS (0.72) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19296785 | 0.90 | KRAS (0.80) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL23092339 | 0.89 | KRAS (0.81) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19296816 | 0.89 | KRAS (0.73) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL19296791 | 0.88 | KRAS (0.76) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL25083247 | 0.88 | KRAS (0.59) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL24535336 | 0.87 | KRAS (0.70) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL16637284 | 0.86 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29373530 | 0.86 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 | |
| SCHEMBL29379971 | 0.86 | KRAS (1.00) | KRASEGFRHMOX2CRYZVAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | CD74, CD2BP2, SERPINB1 | KRAS 4617/4885EGFR 3898/4885HMOX2 3277/4885 |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | KRAS 4804/4885EGFR 3726/4885HMOX2 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.